BioSpace News Archive

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences.

EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million.

Appointment adds diverse commercial experience in new product planning, commercialization strategies and launch readiness spanning 13 career launches, including specific expertise in hematopoietic stem cell mobilization.

Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimab.

Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications.

Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat) targeting carcinoma catabolism.

Pliant Therapeutics, Inc. today announced the dvancement of a fibrosis-directed integrin target into development as part of the Company’s 2019 research and development collaboration with Novartis.

Chandler to Lead Healthcare Interoperability Company to Drive Seamless Collaboration Between Payers and Providers and Optimize the Patient Experience.

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that Ruoxi (Rosy) Hu, Ph.D., from Morningside Technology Advisory, LLC has been appointed to the company’s Board of Directors.